SARS-CoV-2 infection (COVID-19) results predominantly in pulmonary involvement but a direct, virus-induced liver damage may also occur, whose mechanisms are being actively investigated. Accordingly, it appears of utmost importance to monitor liver function and carefully evaluate hepatic safety of the various drugs administered during COVID-19. In this respect, many drugs, biological agents and novel molecules, whose efficacy in COVID-19 is under scrutiny, have also been shown to potentially cause or worsen liver damage. In this article, we review safety data of established as well as promising agents for COVID-19.
All Keywords
【저자키워드】 Azithromycin, Hydroxychloroquine, Remdesivir, Hepatitis, cholestasis, liver failure,
【저자키워드】 Azithromycin, Hydroxychloroquine, Remdesivir, Hepatitis, cholestasis, liver failure,